Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
[Tang, Xue-Ting] Univ South China, Hengyang Med Coll, Inst Neurosci, Hengyang Key Lab Neurodegenerat & Cognit Impairme, Hengyang, Peoples R China.
[Li, Xing] Shaoyang Univ, Sch Basic Med Sci, Shaoyang, Peoples R China.
[Zhou, Cheng-fang] Army Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China.
通讯机构：
[Zhou, CF ] Z
Zhuzhou Cent Hosp, Zhuzhou, Peoples R China.
Army Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China.
语种：
英文
关键词：
Neoadjuvant chemotherapy;bevacizumab;intraperitoneal perfusion;Advanced ovarian cancer;R0 resection The study has no financial support Ovary cancer;chemotherapy;Debulking surgery;R0 resection
Special application for the construction of innovative provinces in Hunan, China No. S2021SFYLJS0026.
机构署名：
本校为其他机构
院系归属：
医学院
摘要：
Objective: This study evaluated the role of neoadjuvant chemotherapy (NACT) with bevacizumab intraperitoneal perfusion in advanced ovarian cancer (AOC). Methods: In this study, 80 patients with advanced epithelial ovarian cancer (stage IIIc or IV) who received NACT at the Central Hospital of Zhuzhou between February 2019 and October 2020 were enrolled. Patients were randomized to receive paclitaxel plus carboplatin (TC) or TC plus intraperitoneal perfusion of bevacizumab (TCB). The effect of chemotherapy was assessed following two cycles of che...
